Deep Bio and Roche Collaborate to Drive AI-Powered Innovations in Digital Pathology

Deep Bio, a leader in AI-powered cancer diagnostics, is excited to announce its collaboration with Roche to integrate its advanced suite of AI algorithms into the navify® Digital Pathology platform. This collaboration aims to enhance digital pathology capabilities, offering a comprehensive menu of AI solutions, starting with DeepDx Prostate, a clinically validated algorithm for prostate cancer analysis.

Deep Bio’s algorithms provide pathologists with precise and efficient diagnostic tools that enhance accuracy in cancer detection, grading, and tumor quantification. By leveraging Roche’s advanced navify^® Digital Pathology Open Environment, Deep Bio seeks to deliver improved diagnostic insights and pathology workflows, making them globally accessible. The seamless integration into existing pathology workflows will leverage AI to unlock new insights and data, driving better treatment decisions.

DeepDx Prostate has undergone extensive testing, analyzing over 700,000 core needle biopsies in the U.S., marking it as one of the most thoroughly vetted solutions in its field. This advanced algorithm offers pathologists accurate AI-enabled prostate cancer diagnosis, gland-level Gleason grading, and tissue and tumor measurements, all within the navify^® Digital Pathology workflows. Deep Bio’s DeepDx Prostate is CE Marked and has been validated through comprehensive clinical studies published in peer-reviewed journals. With distinctions such as the Silver Edison Award and the CES Innovation Award, Deep Bio is dedicated to pioneering innovative technologies to enhance clinical outcomes.

“We are excited to collaborate with Roche, a global leader in diagnostics, to extend the accessibility and impact of our AI solutions,” said Sun Woo Kim, CEO and founder of Deep Bio. “With DeepDx Prostate integrated into the navify^® platform, pathologists worldwide can access powerful diagnostic tools that enhance decision-making and improve patient care in oncology, supported by a global digital ecosystem.”

This collaboration underscores Deep Bio’s commitment to advancing cancer diagnostics and complements Roche’s mission to transform patient care through innovative digital solutions. The integration with navify^® Digital Pathology provides pathologists with streamlined access to state-of-the-art AI technologies, enhancing diagnostic workflows and supporting precision medicine initiatives.

For more information, please visit Deep Bio’s website at www.deepbio.co.kr.

About Deep Bio

Founded in 2015, Deep Bio Inc. is at the forefront of AI-driven solutions for cancer pathology diagnostics, leveraging cutting-edge deep learning technologies to transform the future of cancer care. The company develops in-vitro diagnostic medical device software (IVD SaMD) that enhances diagnostic accuracy and pathologist efficiency, empowering clinicians with data-driven insights for informed decision-making.

Deep Bio’s flagship AI solution, DeepDx Prostate, certified with European CE-IVD, analyzes Whole Slide Images (WSI) to accurately identify and segment cancerous lesions. The software offers comprehensive classification by Gleason pattern, precise tumor localization, and a range of critical metrics, including Gleason score quantification and tumor volume and length assessments, vital for diagnosis, prognosis, and treatment planning.

These AI solutions deliver detailed analysis and reporting, elevating the quality and precision of diagnostic insights for healthcare professionals. Recognized for innovation with the CES Innovation Award in 2024, Deep Bio is committed to advancing pathology workflows and improving patient outcomes worldwide.